Peter Kaiser's most recent trade in Ocular Therapeutix Inc was a trade of 2,810 Common Stock done at an average price of $8.3 . Disclosure was reported to the exchange on Feb. 23, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ocular Therapeutix Inc | Peter Kaiser | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 8.28 per share. | 23 Feb 2026 | 2,810 | 269,108 (0%) | 0% | 8.3 | 23,267 | Common Stock |
| Ocular Therapeutix Inc | Peter Kaiser | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 240,932 | 240,932 | - | - | Stock Option (Right to Buy) | |
| Ocular Therapeutix Inc | Peter Kaiser | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 79,112 | 271,918 (0%) | 0% | 0 | Common Stock | |
| Ocular Therapeutix Inc | Peter Kaiser | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 12.02 per share. | 24 Nov 2025 | 3,007 | 191,433 (0%) | 0% | 12.0 | 36,144 | Common Stock |
| Ocular Therapeutix Inc | Peter Kaiser | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 11.03 per share. | 02 Oct 2025 | 9,653 | 194,440 (0%) | 0% | 11.0 | 106,473 | Common Stock |
| Ocular Therapeutix Inc | Peter Kaiser | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 12.04 per share. | 25 Aug 2025 | 3,011 | 204,093 (0%) | 0% | 12.0 | 36,252 | Common Stock |
| Ocular Therapeutix Inc | Peter Kaiser | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 7.17 per share. | 23 May 2025 | 2,974 | 207,104 (0%) | 0% | 7.2 | 21,324 | Common Stock |
| Ocular Therapeutix Inc | Peter Kaiser | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 6.87 per share. | 24 Feb 2025 | 3,009 | 210,078 (0%) | 0% | 6.9 | 20,672 | Common Stock |
| Ocular Therapeutix Inc | Peter Kaiser | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 9.01 per share. | 25 Nov 2024 | 2,897 | 213,087 (0%) | 0% | 9.0 | 26,102 | Common Stock |
| Ocular Therapeutix Inc | Peter Kaiser | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Oct 2024 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Ocular Therapeutix Inc | Peter Kaiser | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Oct 2024 | 100,000 | 215,984 (0%) | 0% | 0 | Common Stock |